Viewing
|Articles|July 1, 2002

Modified steroid has 'potential' for treating subfoveal CNV in AMD

Author(s)Laszlo Dosa

Fort Lauderdale, FL-Anecortave acetate (Alcon), a chemically modified steroid, acts in a unique way to suppress abnormal blood vessel growth in patients with subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).


Related to this article